Literature DB >> 24988931

Cetuximab for resectable colorectal liver metastasis: new EPOC trial.

Kiyoshi Hasegawa1, Masaru Oba1, Norihiro Kokudo2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24988931     DOI： 10.1016/S1470-2045(14)70216-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.

Authors:  Masaru Matsumura; Kiyoshi Hasegawa; Masaru Oba; Kensei Yamaguchi; Hiroyuki Uetake; Takayuki Yoshino; Satoshi Morita; Keiichi Takahashi; Michiaki Unno; Yasuhiro Shimada; Kei Muro; Nobuhisa Matsuhashi; Masaki Mori; Hideo Baba; Mitsuo Shimada; Yoshihiro Mise; Yoshikuni Kawaguchi; Tatsuo Kagimura; Kiyoshi Ishigure; Akio Saiura; Kenichi Sugihara; Norihiro Kokudo
Journal:  Langenbecks Arch Surg       Date:  2022-02-25       Impact factor: 2.895

Review 2.  Emerging Systemic Therapies for Colorectal Cancer.

Authors:  Christine M Veenstra; John C Krauss
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

Review 3.  Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases.

Authors:  Emily Khoo; Stephen O'Neill; Ewan Brown; Stephen J Wigmore; Ewen M Harrison
Journal:  HPB (Oxford)       Date:  2016-04-20       Impact factor: 3.647

4.  Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis?

Authors:  Torhild Veen; Kjetil Søreide
Journal:  World J Gastrointest Oncol       Date:  2017-03-15

Review 5.  Recurrence after hepatic resection in colorectal cancer liver metastasis -Review article-.

Authors:  B Lintoiu-Ursut; A Tulin; S Constantinoiu
Journal:  J Med Life       Date:  2015

6.  SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.

Authors:  Yi-Jun Zhang; Jie-Wei Chen; Xiao-Sheng He; Hui-Zhong Zhang; Yi-Hong Ling; Jia-Huai Wen; Wei-Hao Deng; Peng Li; Jing-Ping Yun; Dan Xie; Mu-Yan Cai
Journal:  EBioMedicine       Date:  2018-01-09       Impact factor: 8.143
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.